Mannkind Corporation expects to submit a request for a supplemental new drug application meeting to the US Food and Drug Administration for its inhaled human insulin (Afrezza Inhalation Powder).

CHICAGO, June 22, 2025 /PRNewswire/ -- Today, a new study demonstrates inhaled insulin as a safe and effective replacement for rapid-acting meal insulin in children with type 1 diabetes. Results from ...

Researchers have found in a new study that inhaled insulin showed no increased risk of lung cancer compared with regular human insulin (RAA). However, it was associated with a threefold higher ...

A Prescription Drug User Fee Act target date of May 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic ...

MannKind (Nasdaq:MNKD) announced today that it enrolled the first patient in the INHALE-1ST study of its Afrezza inhaled insulin.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Inhaled corticosteroids are often used outside of the ...

Yahoo College & High School Sports is powered by On3, delivering expert recruiting, NIL, and transfer portal news. Type 2 diabetes occurs when the body does not use insulin effectively or does not ...

Type 2 diabetes occurs when the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood sugar levels. Medications aim to lower blood glucose, reduce A1C, and ...